Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Milciclib Phase 2a Trial - Tolerability Update

16 May 2018 07:00

RNS Number : 1999O
Tiziana Life Sciences PLC
16 May 2018
 

Tiziana Life Sciences plc

("Tiziana" or the "Company")

 

Tiziana Life Sciences Announces Interim Analysis Data from an Ongoing Phase 2a Trial of Milciclib Safety and Tolerability in Sorafenib-refractory or -intolerable, Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients

 

Treatment with Milciclib (100 mg once daily; 4 day On/3 day Off every four weeks defining each cycle) was well-tolerated for up to 6 cycles in this population of HCC patients

 

 

London, 16 May, 2018 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and inflammatory diseases, today announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.

 

This phase 2a multi-centre and multi-country clinical trial (CDKO-125A-010) in sorafenib-refractory or -intolerable patients with unresectable or metastatic HCC is being conducted in Greece, Italy and Israel. Since, this was the first trial with milciclib in HCC patients, a second, interim analysis was scheduled following completion of treatment for the first 11 patients before initiating enrolment of the next 20 patients. Thus, demonstration of good tolerability with acceptable incidence of serious adverse events is an important milestone to initiate a phase 2b trial evaluating combination of milciclib with sorafenib (NexavarÒ; Bayer Germany (BAYN.GR)) in HCC patient.

 

Major findings were as follows:

 

· Milciclib treatment was well-tolerated with manageable drug-related toxicities. The IDMC concluded that there were no major signals of tolerability concerns and therefore favours proceeding to expand enrolment.

 

· Four patients have completed the study per protocol (6 cycles of treatment in 6 months). Two of these patients and their care provider opted to continue receiving milciclib at full dose as part of compassionate use. A third patient is awaiting ethical committee (EC) approval.

 

Gabriele Cerrone, Chairman of Tiziana Life Sciences, commented: "Establishment of tolerability of milciclib as a single agent in HCC patients is a key pre-requisite to initiate the phase 2b trial to evaluate dosing, tolerability and clinical activity of milciclib in combination with sorafenib (NexavarÒ; Bayer Germany) in HCC patients.

 

Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences, commented: "we are pleased with the conclusion of IDMC that milciclib treatment showed no major signals of tolerability concerns in sorafenib-refractory or -intolerable HCC patients. These findings are consistent with the findings reported earlier on the long-term tolerability and clinical activity of milciclib in thymic carcinoma, thymoma1 and other solid cancers2. Results from these clinical studies strongly warrant further clinical development of milciclib for treatments of HCC and other cancers".

 

 

Cited References

 

1. Press Release on announcement of clinical data in thymoma and thymic carcinoma.www.tizianalifesciences.com .

2 . Aspeslagh, S., Shailubhai, K., Bahleda, R. et al. (2017). Phase I dose-escalation study of Milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemother Pharmacol. 79:1257-1265

 

About Hepatocellular Carcinoma

Hepatocellular cancer is the 5th most common cancer and the 3rd cause of cancer mortality worldwide. In 2007 the approval by the European Medical Agency (EMA) and Food and Drug Administration (FDA) of sorafenib in HCC represented the first systemic therapy for improving outcome in patients unsuitable for loco-regional and surgical therapies and created a new standard of treatment for the disease. However, although significant in respect to placebo, the benefits of sorafenib are modest; the response rate is less than 3%, the improvement in median survival is 2-3 months and the drug-related symptoms are not ordinary. Therefore, more effective systemic therapy is required for both naive patients presenting with unresectable, advanced stage and those who suffer recurrence after curative treatments (resection, ablation and transplantation).

 

About Milciclib

Milciclib (PHA-848125AC) is a small molecule inhibitor of several cyclin dependent kinases (CDKs) such as CDK1, CDK4, CDK5 and CDK7. CDKs are serine threonine kinases that play crucial roles in progression of the cell cycle from G1 to S phase. Overexpression of CDKs and other downstream signalling pathways that regulate cell cycles have been frequently found to be associated with development of resistance towards chemotherapies. In a phase I study, oral treatment with Milciclib was found to be well-tolerated and the drug showed promising clinical responses in patients with advanced solid malignancies such as in thymic carcinoma, pancreatic carcinoma and colon cancer.

 

About Sorafenib

Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar) is a small molecular multi tyrosine kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (HCC), and radioactive iodine resistant advanced thyroid carcinoma. Treatment with sorafenib induces autophagy, which may suppress tumor growth. However, autophagy can also cause drug resistance.

 

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound Milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-CD3 antibody in clinical development. This phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

For more information go to http://www.tizianalifesciences.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

The content of this announcement has been reviewed and approved for publication by Dr Kunwar Shailubhai, CEO & CSO of the Company.

 

Contacts

 

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

 

+44 (0)20 7493 2853

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner

 

+44 (0)20 7213 0880

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESDGGDUXBBBGIU
Date   Source Headline
30th Mar 202112:30 pmRNSAccustem Update
30th Mar 20217:00 amRNSP2 Study in Moderate to Severe Covid-19 Patients
29th Mar 20211:02 pmRNSUpdated: Gabriele Cerrone, Bloomberg Interview
29th Mar 20217:00 amRNSChairman of Tiziana to give interview on Bloomberg
26th Feb 20217:00 amRNSTiziana Interview to Air on Bloomberg TV
16th Feb 20212:37 pmRNSTiziana at BIO CEO & Investor Digital Conference
5th Feb 20217:10 amRNSDirector/PDMR Shareholding
5th Feb 20217:00 amRNSAPPOINTMENT OF DIRECTOR
3rd Feb 20217:00 amRNSCEO exclusive interview to discuss COVID-19 Trial
2nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20214:36 pmRNSPrice Monitoring Extension
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
2nd Feb 20217:00 amRNSPositive Data: Nasal Administration of Foralumab
27th Jan 20217:00 amRNSTiziana files F-3 Statement with U.S. SEC
26th Jan 20217:00 amRNSUpdated corporate presentation
20th Jan 202111:04 amRNSB. Riley Virtual Oncology Investor Conference
20th Jan 20217:00 amRNSAIM Delisting and Admission to the Main Market
13th Jan 20217:00 amRNSAppointment of Chief Medical Officer
11th Jan 20214:46 pmRNSTiziana at J.P. Morgan Healthcare Conference 2021
11th Jan 20212:48 pmRNSTiziana to Present at Biotech Showcase Digital
4th Jan 20219:05 amRNSSecond Price Monitoring Extn
4th Jan 20219:00 amRNSPrice Monitoring Extension
4th Jan 20217:00 amRNSCompletion of Foralumab Clinical Trial in Brazil
18th Dec 202011:13 amRNSPublication of Prospectus
17th Dec 20203:00 pmRNSNotification of Admission to the Main Market
10th Dec 20207:00 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTiziana Life Sciences to Host Investor Update Call
18th Nov 20202:00 pmRNSDirector/PDMR Shareholding
11th Nov 20207:00 amRNSPhase 1b/2 Clinical Trial - Crohn's Disease
9th Nov 20202:05 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
2nd Nov 20209:05 amRNSSecond Price Monitoring Extn
2nd Nov 20209:00 amRNSPrice Monitoring Extension
2nd Nov 20207:00 amRNSInitiation of Clinical Trial for COVID-19 Patients
29th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
29th Oct 20207:00 amRNSDemerger Update and Timetable Confirmation
28th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
27th Oct 20204:00 pmRNSDemerger of StemPrintER
26th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
22nd Oct 20204:36 pmRNSIssue of Equity on Exercise of Warrants
21st Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
20th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
2nd Oct 202012:00 pmRNSResult of GM
30th Sep 20207:00 amRNSHalf-year Report
25th Sep 20204:40 pmRNSSecond Price Monitoring Extn
25th Sep 20204:35 pmRNSPrice Monitoring Extension
25th Sep 20207:00 amRNSInterview - Bloomberg International
21st Sep 20202:11 pmRNSPublication of Research Note
21st Sep 20207:00 amRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.